1 Replication origins
are 'licensed' for a single initiation event by loading
2 lent, inactivated influenza vaccine (TIV-HD)
was licensed for adults aged >/=65 years.
3 -von Willebrand factor nanobody caplacizumab
was licensed for adults with immune-mediated thrombotic
4 forms, many viral vector-based vaccines have
been licensed for animals.
5 of endotoxin priming, the NLRP3 inflammasome
is licensed for ATP-induced release of processed IL-18,
6 st the SARS-CoV-2 protease 3CL(pro) that has
been licensed for clinical use.
7 tic vaccine from one manufacturer having now
been licensed for commercial use and the expectation tha
8 clinical trials and ChAdOx1 nCoV-19 has now
been licensed for emergency use for COVID-19.
9 d-generation tyrosine kinase inhibitors have
been licensed for first-line use.
10 s vaccines, Rotarix (RV1) and RotaTeq (RV5),
were licensed for global use in 2006.
11 OCVs have
been licensed for &
gt;20 years, but their potential for pre
12 New vaccines have
been licensed for hepatitis A, varicella, and typhoid.
13 iruses for which no vaccines or therapeutics
are licensed for human use.
14 e, only a few adjuvants and delivery systems
are licensed for human use.
15 ree (abciximab, eptifibatide, and tirofiban)
are licensed for human use.
16 ) have been shown to be efficacious and have
been licensed for human use, the surface glycoproteins h
17 ine efficacy has been reported and none have
been licensed for human use.
18 MF59-adjuvanted influenza vaccines
were licensed for human vaccination, but the detailed me
19 The first gene therapy medicines have
been licensed for marketing and several more are advanci
20 Zoster vaccine
is licensed for persons aged 50 years or older, but its
21 PDE5 inhibitors (eg, sildenafil)
are licensed for PH, but a role for PDE2 in lung physiol
22 ratory syncytical virus (RSV) fusion protein
are licensed for pre-treatment of infants.
23 Adenoviral-vectored vaccines
are licensed for prevention of severe acute respiratory
24 children, and a live, oral vaccine may soon
be licensed for prevention.
25 Live-attenuated influenza vaccine (LAIV)
was licensed for prophylaxis of children 2-17 years old
26 Multiple biologic treatments
are licensed for psoriasis.
27 malaria-exposed Malian and U.S. individuals
were licensed for reactivity to P. falciparum parasites
28 in genome stability in eukaryotic cells, DNA
is licensed for replication only after the cell has comp
29 the H. influenzae type b conjugate vaccines
were licensed for routine immunization of infants.
30 te mitosis and early G1, replication origins
are licensed for subsequent replication by loading heter
31 te mitosis and early G1, replication origins
are licensed for subsequent use by loading complexes of
32 es widely used within PICUs neither of which
being licensed for that use.
33 tazone, are insulin sensitizing agents, that
are licensed for the management of hyperglycaemia.
34 fumarate (TDF) and adefovir dipivoxil (ADV)
are licensed for the treatment of HIV-1 and HBV infectio
35 blockade with abatacept (CTLA4-Ig) will soon
be licensed for the treatment of rheumatoid arthritis -
36 l (MenB) four component vaccine (4CMenB) has
been licensed for the prevention of invasive disease cau
37 Several novel therapies have
been licensed for the treatment of myeloma in recent yea
38 diterpenoids include ingenol mebutate, which
is licensed for the treatment of a precancerous skin con
39 Infliximab
is licensed for the treatment of Crohn's disease (CD) an
40 Etanercept
is licensed for the treatment of RA, including juvenile
41 e ligand of Toll-like receptor-7 (TLR7) that
is licensed for the treatment of viral infections and ca
42 , including juvenile RA, and, more recently,
was licensed for the treatment of psoriatic arthritis.
43 ts were newly licensed registered nurses who
were licensed for the first time between August 1st, 200
44 Omalizumab
is licensed for therapy in severe allergic asthma with a
45 re sampled, but only a subset of those sites
is licensed for TnsC and TnsB recruitment, revealing a c
46 GLP1 receptor (GLP-1R) agonists
are licensed for treating type 2 diabetes mellitus but h
47 ivated protein C (rhAPC [Xigris; Eli Lilly])
is licensed for treating human patients with severe seps
48 dditional analog, Pomalidomide, has recently
been licensed for treatment of multiple myeloma, and is
49 These analogues
are licensed for type 2 diabetes, but their efficacy in
50 MARV outbreaks, no vaccines or therapeutics
are licensed for use in humans.
51 udy, we provide a roadmap for how pesticides
are licensed for use in the European Union.
52 Two rotavirus vaccines have recently
been licensed for use in >80 countries worldwide but not
53 clinical trial and a similar DNA vaccine has
been licensed for use in horses.
54 o herpes simplex virus 2 (HSV-2) vaccine has
been licensed for use in humans.
55 A vaccine (4CMenB) has now
been licensed for use in the European Union, comprising
56 alent seasonal influenza vaccine (RIV4) have
been licensed for use in the USA.
57 alent human papillomavirus (HPV) vaccine has
been licensed for use in women and men up to age 45 year
58 on-based prognostic breast cancer tests have
been licensed for use.
59 ce 1969, several rubella virus vaccines have
been licensed for use; however, until the 1990s, use of
60 andidates in clinical trials, only Dengvaxia
is licensed for use in DENV seropositive individuals.
61 ials in lupus nephritis, no second line drug
is licensed for use in induction of remission in lupus n
62 o standard-dose influenza vaccines (SD-IIV),
is licensed for use in people aged 65 years.
63 ive agent of Argentine hemorrhagic fever, it
is licensed for use only in areas where Argentine hemorr
64 occal conjugated polysaccharide vaccine PC7V
was licensed for use among children in 2000.
65 drivalent human papillomavirus (HPV) vaccine
was licensed for use in 9- through 26-year-old females i
66 p A meningococcal conjugate vaccine (PsA-TT)
was licensed for use in sub-Saharan Africa in 2009.
67 otype-specific disease before and after PCV7
was licensed for use.